Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer - Concepedia

Concepedia

Publication | Closed Access

Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

157

Citations

35

References

2001

Year

Michelle A. Rudek, William D. Figg, Valerie Dyer, William L. Dahut, Maria L. Turner, Seth M. Steinberg, David J. Liewehr, David Köhler, James M. Pluda, Eddie Reed

Journal of Clinical Oncology

Abstract

COL-3 induced disease stabilization in several patients who had a nonepithelial type of malignancy. Phototoxicity was dose-limiting. We recommend the dose of 36 mg/m2/d for phase II trials.

References

	Year	Citations

Page 1